Business
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal
About this update from Cervomed Inc.
[{"type":"text","content":"Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible Findings also correlate with previously reported results on neflamapimod’s observed effects on a blood biomarker of neurodegenerative disease activity, providing additional evidence of neflamapimod’s potential to act on the underlying disease process in dementia with Lewy Bodies (DLB) DLB is the second most common progressive dementia, affecting millions worldwide, and has no approved treatments in the United States or European Union BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Today at the 2026 AAN Annual Meeting in Chicago, the first-ever, placebo-controlled magnetic resonance imaging (MRI) analyses providing evidence that neflamapimod may increase the size and enhance the function of the basal forebrain in patients with dementia with Lewy bodies (DLB) were presented by CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company). Basal forebrain (BF) atrophy is the primary pathogenic driver of disease expression and progression in DLB. “These findings from further analysis of the RewinD-LB Phase 2b clinical trial are consistent with preclinical data, including prior studies with neflamapimod, which show that basal forebrain atrophy in DLB might be reversible,” said Menno Schoonheim, Ph.D., who led the MRI analysis and serves as Scientific Director of the MS Center at Amsterdam University Medical Center. “Importantly, the study showed that changes in volume coincide with functional brain changes. This could indicate that the observed treatment-related forebrain volume changes in DLB could reflect a resolution of synaptic dysfunction and cellular shrinkage. If proven to be the case, this could change our perspective on neuroprotection or even reversal of volume loss. The observed right-sided involvement aligns to regions of the basal forebrain reported to be most impacted in Lewy body disorders.” “Therapies such as neflamapimod that target basal forebrain cholinergic dysfunction and degeneration can teach us something new about the brain, and especially brain volume changes in conditions like DLB,” Dr. Schoonheim added. “Combining structural and functional outcomes creates the opportunity to detect treatment effects over shorter timeframes and in smaller studies,...